Results 101 to 110 of about 1,466,333 (379)

Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing [PDF]

, 2017
The anti-FcRH5/CD3 T cell-dependent bispecific antibody (TDB) targets the B cell lineage marker FcRH5 expressed in multiple myeloma (MM) tumor cells. We demonstrate that TDBs trigger T cell receptor activation by inducing target clustering and exclusion ...
Clark, V, Cook, R, Danilenko, D, DiCara, D, Ellerman, D, Harris, MJ, Hristopoulos, M, Hötzel, I, James, JR, Johnston, J, Junttila, TT, Lee, GY, Li, J, Luis, E, McCarty, L, Menzies, SA, Nakamura, R, Slaga, D, Stagg, NJ, Sukumaran, S, Sumiyoshi, T, Totpal, K, Wu, TD, Ye, Z   +23 more
core   +2 more sources

Advancements in DNA‐Driven Precision Modulation of Cell Surface Receptor for Programmable Cellular Functions

Advanced Science, EarlyView.
DNA‐Based Genetic and Non‐Genetic Tools for Receptor Engineering. This review highlights recent advances in DNA‐based strategies for receptor engineering, including genetic approaches like domain fusion and site‐directed mutagenesis, as well as non‐genetic methods using functional nucleic acids, DNA nanostructures, and dynamic DNA reactions.
Hexin Nan, Ming Cai, Yiyu Wang, Hong‐Hui Wang, Zhou Nie   +4 more
wiley   +1 more source

A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor-specificity

mAbs
P-cadherin (pCAD) and LI-cadherin (CDH17) are cell-surface proteins belonging to the cadherin superfamily that are both highly expressed in colorectal cancer.
Alyssa Synan, Nila C. Wu, Roberto Velazquez, Thomas Gesner, Claude Logel, Kathrin Mueller, Andrew Green, Patrizia Barzaghi-Rinaudo, Quincey Simmons, Samuele Mercan, Xingyi Shi, Xun Li, Vivek Sagar, Joshua Korn, Margaret McLaughlin, William R. Tschantz, Dominik Hainzl, Anthony Malamas, Thomas Huber, Regis Cebe, Kathleen T. Xie, Joseph A. D’Alessio   +21 more
doaj   +1 more source

Intein mediated high throughput screening for bispecific antibodies

mAbs, 2020
Bispecific antibodies comprise extremely diverse architectures enabling complex modes of action, such as effector cell recruitment or conditional target modulation via dual targeting, not conveyed by monospecific antibodies.
Tim Hofmann, Johannes Schmidt, Elke Ciesielski, Stefan Becker, Thomas Rysiok, Mark Schütte, Lars Toleikis, Harald Kolmar, Achim Doerner   +8 more
doaj   +1 more source

Emerging new therapeutic antibody derivatives for cancer treatment

Signal Transduction and Targeted Therapy, 2022
Monoclonal antibodies constitute a promising class of targeted anticancer agents that enhance natural immune system functions to suppress cancer cell activity and eliminate cancer cells.
Shijie Jin, Yanping Sun, Xiao Liang, Xinyu Gu, Jiangtao Ning, Yingchun Xu, Shuqing Chen, Liqiang Pan   +7 more
doaj   +1 more source

FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity

Clinical Cancer Research, 2020
Purpose: Although programmed death-ligand 1 (PD-L1) antibody–based therapy has improved the outcome of patients with cancer, acquired resistance to these treatments limits their clinical efficacy.
Matthew Kraman, Mustapha Faroudi, N. Allen, K. Kmiecik, D. Gliddon, Claire J Seal, A. Koers, M. Wydro, Sarah Batey, J. Winnewisser, L. Young, M. Tuna, J. Doody, Michelle Morrow, N. Brewis   +14 more
semanticscholar   +1 more source

Phenylalanine‐Based DNA‐Encoded Chemical Libraries for the Discovery of Potent and Selective Small Organic Ligands Against Markers of Cancer and Immune Cells

Advanced Science, EarlyView.
FM‐DEL1 and FM‐DEL2 are constructed by installing one or two sets of building blocks on a phenylalanine central scaffold. FM‐DELs are screened against markers of prostate, and renal cell carcinoma, and against an immunological target expressed on the surface of natural killer cells.
Francesca Migliorini, Andrea Ciamarone, Sheila Dakhel Plaza, Tony Georgiev, Marta Mascellani, Emanuela Sabato, Giulio Vistoli, Ilaria Biancofiore, Nicholas Favalli, Emanuele Puca, Sebastian Oehler, Dario Neri, Samuele Cazzamalli   +12 more
wiley   +1 more source

Relative Contribution of Framework and CDR Regions in Antibody Variable Domains to Multimerisation of Fv- and scFv-Containing Bispecific Antibodies

Antibodies, 2018
Bispecific antibodies represent an emerging class of antibody drugs that are commonly generated by fusion of Fv or scFv antigen binding domains to IgG or Fab scaffolds.
Pallavi Bhatta, David P. Humphreys
doaj   +1 more source

Antibody-Based Strategies to Prevent and Treat Influenza [PDF]

, 2015
Passive immunization using antibodies is a promising alternative to other antiviral treatment options. The potential for seasonal protection arising from a single injection of antibodies is appealing and has been pursued for a number of infectious agents.
Sasisekharan, Ram, Shriver, Zachary, Trevejo, Jose M.   +2 more
core   +1 more source

A Novel Class of Multi‐substituted Diaryl Scaffold Derivatives Inhibit Glioblastoma Progression by Targeting CD155

Advanced Science, EarlyView.
Structural modification of clofoctol yielded a novel blood‐brain barrier‐permeable compound, B7, featuring a multi‐substituted diaryl scaffold. B7 demonstrates potent anti‐glioblastoma activity by suppressing glioblastoma stem cells proliferation, migration, and invasion through interactions with five key residues of poliovirus receptor cell adhesion ...
Yong‐jian Wang, Ting Sun, Si‐tu Xue, Zhong‐di Cai, Hong Yi, Miao Lv, Shi‐bo Kou, Rui Liu, Xiao‐zhong Peng, Zhuo‐rong Li   +9 more
wiley   +1 more source